Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Thales Helps Lunit Accelerate the Growth of AI-based Software Cancer Diagnostic Solutions
Thales, a global leader in software monetization and licensing, is collaborating with Lunit, a global […]
Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution
Lunit, a leading global provider of AI-powered cancer solutions, today announced that its AI solution […]
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
Lunit, a leading medical AI provider, today announced it has raised $61 million in its Pre-IPO fundraising […]
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round
Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more